▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1499 by analyst upside · 2026-06-27
GLUE
Monte Rosa Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+45.1%
implied upside to consensus target
Current Price $22.29
Consensus Target $32.33
Bull Target $37.0
Bear Target $29.0
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $4.12
52-Week High $25.77
YTD Return +45.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -12.3x
EPS (TTM) $-1.52
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $43M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.12
52-Week High $25.77
Current Price $22.29
Bear Target $29.0
Bull Target $37.0
● Now $22.29 ● Target $32.33
TRADING DATA
Avg Volume 1.0M
YTD Return +45.6%
Analyst Count 6
Consensus Buy
Upside to Target +45.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Monte Rosa Therapeutics, Inc. (GLUE) is currently trading at $22.29 with a Wall Street consensus price target of $32.33, implying potential upside of 45.1% over the next 12 months. 6 analysts currently cover GLUE, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $37.0, while the most cautious has a target of $29.0.

GLUE operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 45.6% year-to-date and is currently trading near the upper end of its 52-week range of $4.12 – $25.77.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy
ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy
ANIP +33.4%
ANI Pharmaceuticals, Inc.
$2B · P/E 21.3x · Buy
HRMY +25.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 14.3x · Buy
PBH +35.2%
Prestige Consumer Healthcare Inc.
$2B · P/E 12.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GLUE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan — Reiterated
Overweight → Overweight 2026-05-11 43% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2026-03-18 62% win rate (8 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-03-18 Building track record
Piper Sandler reit
Overweight → Overweight 2026-01-14 14% win rate (7 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-01-08 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-01-08 62% win rate (8 calls)
Wells Fargo ↑ Upgrade
Equal-Weight → Overweight 2025-12-16 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2025-11-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →